Expert predicts more CROs will buy trial sites after Icon deal

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Contract research organization, Clinical trial

Expert predicts more CROs will buy trial sites after Icon deal
Growth-hungry CROs will buy trial sites according to David Blume from Edgemont Capital Partners, who told us Icon's acquisition of PMG Research is part of an emerging trend.

Dublin, Ireland-based Icon announced it had bought PMG Research on Monday​, explaining that the organisation's 48 clinical centres in North Carolina, South Carolina, Tennessee and Illinois would help it accelerate patient recruitment.

Icon is not the first contract research organisation (CRO) to have reached out to independent trial sites in the past couple of months.

In September​, PRA partnered with the Alliance for Multispecialty Research (AMR), a network of 20 independent research centres in the US, to accelerate recruitment in its clients’ vaccine studies.

A few months earlier PPD​ formalized relationships with eight investigator sites to create a paediatric investigator network (PIN) to "speed trial start-up, more predictably enrol patients and offer higher quality data to clients.​"

Others like Parexel – a fellow Pfizer strategic partner with Icon – have also sought to connect with trial sites.

In February​ the firm told us it aimed to expand its then 180-strong clinical trial site alliance network to accelerate patient recruitment.

Patient recruitment

The major difference with Icon’s deal is that it is an acquisition.

However, it is not likely to be the last according to David Blume, managing director of healthcare deal brokers Edgemont Capital Partners, who told us the contract research sector’s bete noire – patient recruitment – would be the catalyst.

CROs and other companies focused on addressing challenges in subject recruitment are increasingly looking to acquire sites to build their own in-house capability rather than rely on third party service providers.​ 

Research sites are the last mile in clinical research and far and away represent the most fragmented service component​” Blume said, adding that the economies of scale provided by owning sites will improve clinical trial performance in both quality and speed.

As CROs continued to seek future growth, site consolidation offers multiple benefits from improving service to opening an avenue to additional growth​” he continued, adding that “and we see this trend increasing​.”

Related news

Related products

show more

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us

Products

View more

Webinars